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Abstract
Background: Transcatheter aortic valve implantation (TAVI) brings symptom relief and improvement in health-related
quality of life (HRQoL) in the majority of patients treated for symptomatic, severe aortic stenosis. However, there is a
substantial group of patients that do not benefit from TAVI. The aim of this study is to investigate the impact of frailty
on HRQoL 1 year after TAVI.
Methods: The TAVI Care & Cure Program is an ongoing, prospective, observational study including patients referred for
TAVI to our institution. A comprehensive geriatric assessment was performed to evaluate existence of frailty using the Erasmus
Frailty Score (EFS). HRQoL was assessed using the EQ-5D-5 L at baseline and 1 year after TAVI.
Results: 239 patients underwent TAVI and completed HRQoL assessment 1 year after TAVI. Seventy (29.3%) patients were
classified as frail (EFS ≥ 3). In non-frail patients, the EQ-5D-5 L index did not change (0.71(± 0.22) to 0.68(± 0.33) points,
P = 0.22); in frail patients, the EQ-5D-5 L index decreased from 0.55(±0.26) to 0.44 points (±0.33) (P = 0.022). Frailty
was an independent predictor of deteriorated HRQoL 1 year after TAVI (OR 2.24, 95% CI 1.07–4.70, P = 0.003). In frail
patients, the absence of peripheral artery disease (OR 0.17, 95% 0.05–0.50, P = 0.001) and renal dysfunction (OR 0.13,
95% CI 0.04–0.41, P =<0.001) at baseline was associated with improved HRQoL 1 year after TAVI.
Conclusion: Frailty is associated with deterioration of HRQoL 1 year after TAVI. Notably, HRQoL did improve in frail
patients with no peripheral arterial disease or renal impairment at baseline.
Keywords:Aortic stenosis (AS),Transcatheter aortic valve implantation (TAVI),Mortality,Quality of life,EQ-5D,Frailty,Older
people
Key points
• Frailty is an independent predictor of deteriorating quality of life 1 year after TAVI.
• In frail patients, quality of life deteriorated 1 year after TAVI with no change in self-rated health status.
• In frail patients, the absence of peripheral artery disease and renal dysfunction is associated with improvement of quality of
life.
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Introduction
Aortic stenosis (AS) is a common valve disease in older
patients affecting about 3% of the population above 65 years.
If not treated, the risk of mortality and deterioration
of health-related quality of life (HRQoL) is high [1–3].
HRQoL of patients with severe AS is impaired due to
symptoms of impaired exercise tolerance, dyspnea and
eventually angina pectoris and/or syncope [4]. TAVI is
increasingly used to treat patients with AS and is proven
to be safe and effective in a wide variety of patient groups,
including older patients [5–7]. Although the indication
for TAVI has expanded to low-risk patients, the majority
of patients who undergo TAVI are old and frail and have
substantial comorbidities. For this specific population, the
absolute gain in years may be of less importance than
improving their HRQoL.
Previous studies showed an improvement of HRQoL
in the majority of patients who underwent TAVI [8–10].
However, some patients do not report improvement in
HRQoL [10,11]. Little is known on the factors determining
lack of improvement of even deterioration of HRQoL after
TAVI. Frailty has proven to be associated with an increased
mortality and a higher rate of poor outcome up to 1 year
after TAVI [12,13], but studies on the impact of frailty on
HRQoL after TAVI are limited [11]. The aim of this study,




The study population consists of 239 patients who under-
went TAVI (November 2013–June 2018) within the frame
work of the TAVI Care & Cure program [14]. In brief, the
TAVI Care & Cure Program is a prospective single-centre
multidisciplinary observational cohort study that was initi-
ated in November 2013 and consists of a prospective collec-
tion of a comprehensive set of predefined cardiovascular and
non-cardiovascular data including a comprehensive geriatric
assessment (CGA) and baseline characteristics in addition
to procedural and postoperative data of all patients referred
for and treated with TAVI. There were no specific exclusion
criteria. Treatment decision and strategy were decided during
the multidisciplinary heart team meeting (interventional car-
diologists, cardiac surgeons, anaesthesiologists, geriatricians
and a TAVI-nurse coordinator) [15,16]. The TAVI Care &
Cure Program was approved by the Medical Ethics Com-
mittee of the Erasmus University Medical Center (MEC-
2014-277) and was conducted according to the Helsinki
Declaration. All patients provided written informed consent.
Cardiology assessment
Cardiology assessment included determining symptoms
using the New York Heart Association (NYHA) classification
and the Canadian Cardiovascular Society (CCS) grading of
angina pectoris, medical history including cardiovascular
and non-cardiovascular comorbidities (Appendix A1 for the
complete list of comorbidities), physical examination, labo-
ratory assessment and electrocardiogram. Echocardiography,
coronary angiography and multislice computed tomography
(MSCT) were examined to evaluate the condition of the
aortic valve and to determine access site [17].
Comprehensive geriatric assessment
In the CGA, the following frailty domains and instruments
were examined: cognition, measured by the Mini-Mental
State Examination (MMSE) [18]; strength, measured by the
handgrip strength test [19]; (mal)nutrition, measured by the
Malnutrition Universal Screening Tool (MUST) [20]; inac-
tivity in basic activities of daily living, measured by the Katz
index (Katz ADL) [21]; inactivity in instrumental activities
of daily living, measured by the Lawton and Brody index
[22]; and limitation of mobility using the Timed Up and Go
Test (TUGT) [23] and 5 Meter Gait Speed Test (5MGST)
[24]. A comprehensive explanation of the frailty domains
and cutoff points can be found in Appendix A2. Frailty was
defined by the Erasmus Frailty Score (EFS) that has been
reported to be associated with postoperative delirium and
1-year mortality [12]. The EFS uses five geriatric domains:
cognition, strength, (mal)nutrition, inactivity in basic activ-
ities of daily living and inactivity in instrumental activities
of daily living. Patients were considered frail if the score
on three or more domains was below predefined standard
cutoff points [12]. The Cumulative Illness Rating Scale for
Geriatrics (CIRS-G) was used to rate existing comorbidities,
measuring chronic medical illness burden while taking into
account the severity of the chronic disease in 14 items
representing individual body systems. The cumulative final
score can vary theoretically from 0 to 56. The severity index is
calculated dividing the total score through the total number
of categories endorsed [25].
Quality of life measurement
HRQoL was assessed using the EuroQol 5 dimensions ques-
tionnaire (EQ-5D-5 L) preoperatively and 1 year after TAVI.
The EQ-5D-5 L is a generic health utility HRQoL instru-
ment and is qualified for measuring health status within
an older population [26]. The EQ-5D-5 L consists of five
dimensions of health (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression), each of which is
divided in five levels of functioning: no problems (level 1),
some or moderate problems (levels 2 and 3) and severe or
extreme problems (levels 4 and 5). Based on the responses
to these dimensions, a single index value is estimated using
a general population-based algorithm, ranging from −0.446
to 1 (a value of 1 indicating full health, while a value lower
than 0 represents a status considered to be worse than death).
The EQ-5D index value scores are country specific. Value
sets and coefficients for the Dutch population were used for
the estimations of the individual EQ-5D index [27]. The
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analogue scale). This is a standardised instrument to assess
self-rated health on a scale with a scoring range from 0 (worst
imaginable health state) to 100 (best imaginable health state)
[28]. To incorporate data on mortality into the EQ-5D-5 L
outcome, we divided our patient group into patients with
either improvement or deterioration in HRQoL 1 year after
TAVI. Improvement was defined as survival without any
worsening in the EQ-5D index 1 year after TAVI compared
to baseline. Deterioration was defined as death within 1 year
or a decrease in the EQ-5D-5 L index 1 year after TAVI. This
approach is comparable to a method previously used for the
Kansas City Cardiomyopathy Questionnaire [29].
TAVI procedure
TAVI was initially performed under general anaesthesia and
from September 2015 onwards under local anaesthesia, using
the transfemoral approach as default choice. After TAVI,
patients were admitted to the intensive care unit for early
monitoring for a minimum of 4 h before transferring to the
general cardiology ward. From the day of admittance up to
at least 3 days after procedure, the geriatric consulting team
is involved in delirium vigilance and preventing functional
decline during admission.
Statistical analysis
Continuous data are expressed as mean values with stan-
dard deviations ± SD. Differences between patients who
were frail and non-frail were compared with nonparametric
equivalents (Mann–Whitney–Wilcoxon U test). Categorical
values were noted as percentages, and differences between
patients who were frail and non-frail were compared with
the chi-square test or Fisher’s exact test as appropriate. Paired
sample t tests were used to analyse the difference between
HRQoL measurements on baseline and 1-year follow-up.
The Reliable Change Index (RCI) was calculated measur-
ing the difference between the EQ-5D-5 L index value
on baseline and the EQ-5D-5 L index value at follow-up
divided by the standard error of the difference between
both EQ-5D-5 L index values. For the outcome deterio-
ration of HRQoL 1 year after TAVI, univariate analysis
was performed, entering variables with a P-value <0.10 in
the multivariate regression models. For the multivariable
model, odds ratios (OR) and corresponding 95% confidence
interval (95% CI) were computed, adjusted for age, sex,
EQ-5D-5 L index on baseline, current smoking, peripheral
artery disease, renal dysfunction, limitation of mobility (5
Meter Gait Speed Test) and frailty (EFS). P-value <0.05
(two-tailed) was considered statistically significant. Statistical
analysis was performed using IBM Statistical Package for
Social Science (SPSS) for Windows version 25.
Results
Patients characteristics
A total of 239 patients with severe symptomatic AS who
underwent TAVI between November 2013 and May 2019
Table 1. Baseline characteristics (n = 239)
Age (years, ±SD) 80.8 (±6.5)
Male gender (%) 119 (49.8%)
BMI (kg/m2, ±SD) 27.2 (± 4.9)
Cardiovascular risk factors
Hypertension (%) 197 (82.8%)
Current smoker (%) 23 (10.2%)
Diabetes mellitus (%) 79 (33.1%)
Hypercholesterolemia (%) 151 (63.2%)
Peripheral artery disease (%) 108 (45.2%)
Comorbidities
CIRS G score (points, ±SD) 15.4 (±4.4)
CIRS G index (points, ±SD) 1.90 (±0.3)
Symptoms
NYHA class 3 or 4 (%) 149 (62.3%)
Angina CCS classification 3 or 4 (%) 29 (12.1%)
Vertigo (%) 93 (38.9%)
Echocardiography
Aortic valve area (cm2, ±SD) 0.8 (±0.2)
Peak AoV PG (mmHg, ± SD) 66.4 (±21.6)
Peak AoV velocity (m/s, ±SD) 4.0 (±0.7)
Frailty indices
Cognitive impairment probable (%) 74 (31%)
Malnutrition probable (%) 27 (11.3%)
Limitation of mobility, TUGT (%) 35 (14.6%)
Limitation of mobility, 5MGS (%) 153 (64%)
Reduced muscle strength, (%) 113 (47.3%)
Limitation in ADL activity (%) 70 (29.3%)
Limitation in iADL activity (%) 128 (53.6%)
Erasmus Frailty Score ≥ 3 (%) 70 (29.3%)
Abbreviations used: BMI, body mass index; CIRS-G, Cumulative Illness Rating
Scale for Geriatrics; NYHA, New York Heart Association functional class; CCS,
Canadian Cardiovascular Society; AoV, aortic valve; PG, pressure gradient;
TUGT: Timed Up and Go test; 5MGS, 5 Meter Gait Speed Test; ADL, activities
of daily living; iADL, instrumental activities of daily living.
were assessed with CGA at baseline. About, 197 patients
completed HRQoL follow-up after 12 months and 42
patients died within 12 months after TAVI. The mean age of
patients was 80.8 ± 6.5 years and 49.8% were men. Seventy
(29.3%) patients were frail (Erasmus Frailty Score ≥ 3).
Detailed baseline characteristics are shown in Table 1.
New York Heart Association functional class
Preoperatively, 62.3% (n = 149) were in NYHA class III
or IV (frail patients 81.4%; non-frail patients 54.5%,
P < 0.001). One year after the procedure, 51.5% of the
frail patients reported an improvement in NYHA functional
class compared to 60.6% of non-frail patients (P = 0.224).
One year after TAVI, 20.4% of the frail patients were still
in NYHA class III or IV vs. 14.3% of the non-frail patients
(P = 0.67) (Appendix A3).
Quality of life 1 year after TAVI (Eq-5D-5 L)
Improvement of HRQoL was seen in 125 patients (52.3%).
Deterioration and/or death within 1 year was found in 110
patients (46.0%). Improvement of HRQOL at 1 year after
TAVI was seen more often in non-frail patients as compared
to frail patients (58.3 versus 39.7% respectively, P = 0.014).
In frail patients, the EQ-5D-5 L index decreased from 0.55
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Table 2. Quality of life at baseline and 12 months follow-up in frail and non-frail patients
Frail patients Baseline 12 months P-value∗
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
EQ-5D index 0.55 (± 0.26) 0.44 (±0.33) 0.022
EQ-VAS 58.4 (±16.8) 63.4 (±14.6) 0.095
Non-frail patients
EQ-5D index 0.71 (±0.22) 0.68 (±0.33) 0.22
EQ-VAS 66.2 (±16.8) 72.0 (±14.8) <0.001
Values are expressed as means (±). VAS, visual analogue scale.
Table 3. Predictors of deterioration of quality of life 1 year after TAVI
Variable OR 95%CI P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age 1.01 0.96–1.07 0.647
Gender 1.13 0.56–2.27 0.737
Eq5D-5 L index on baseline 10.62 2.32–48.52 0.002
Current smoker 3.21 1.06–9.77 0.040
PAD 1.40 0.73–2.66 0.312
Renal dysfunction 2.12 1.11–4.04 0.023
Limitation of mobility (5mGST) 2.29 1.35–6.17 0.006
Frailty (EFS) 2.25 1.07–4.70 0.003
Abbreviations used: PAD, peripheral arterial disease; 5mGST, 5 meter Gait Speed Test; EFS, Erasmus Frailty Score.
(P = 0.022). The VAS score did not change (58.4 points
(±16.8) and 63.4 points (±14.6) (P = 0.095)). In non-frail
patients, the EQ-5D-5 L index did not change from baseline
to 1 year after TAVI (0.71 points (±0.22) vs 0.68 points
(±0.33) (P = 0.22)), but the VAS score did increase (66.2
points (±16.8) to 72.0 points (± 14.8) <0.001) (Table 2).
The RCI was 2.2; concluding changes in EQ-5D-5 L index
values are assumed to be reliable.
The baseline Eq5D dimensions and the change in Eq5D
dimensions are shown in Appendix A4.
Frailty was an independent predictor of deterioration of
HRQoL 1 year after TAVI (OR 2.24, 95% CI 1.07–4.70).
Current smoking (OR 3.21, 95% CI 1.06–9.77), renal dys-
function (OR 2.12, 95% CI 1.11–4.04) and limited mobil-
ity (5MGST) (OR 2.29, 95% CI 1.35–6.11) were other
predictors (Table 3). Postoperative delirium was associated
with deterioration of HRQoL 1 year after TAVI in models
adjusted for baseline predictors (univariate P-value<0.10)
and baseline QoL status (OR 3.45, 95% CI 1.27–9.4). In
frail patients, the absence of peripheral artery disease (OR
0.17, 95% 0.05–0.50) and renal dysfunction (OR 0.13,
95% CI 0.04–0.41) at baseline was associated with improved
HRQoL 1 year after TAVI.
Nineteen (27.1%) frail patients died within 1 year after
TAVI versus 22 (13.3%) non-frail patients (P = 0.014).
Discussion
In this study, we found that frailty at baseline is an indepen-
dent predictor of deterioration of HRQoL 1 year after TAVI.
In frail patients HRQoL deteriorated where the self-rated
health status did not change. In non-frail patients HRQoL
did not deteriorate and the self-rated health status improved.
Importantly, in the absence of peripheral arterial disease and
renal impairment, frail patients did experience improvement
in HRQoL. In both frail and non-frail patients, we found
an improvement in New York Heart Association functional
class after TAVI.
Previous studies found an improvement in HRQoL after
TAVI in the majority of patients [8,10,30]; however, even
in large registry studies [10,30], there was a sizable group
of patients who did not derive benefits in terms of improv-
ing HRQoL. Several factors including comorbidities, high
mortality risk and frailty have been associated with poor
outcome after TAVI [11–13,31,32]. A previous study found
that if frailty was the indication for TAVI, the risk of not
improving HRQoL after 1 year was twice as high com-
pared to patients that had more technical indications for
TAVI [8]. A substudy of the PARTNER Trial showed that
frailty was associated with impaired HRQoL 6 months after
TAVI, but this association was not found after 12 months
of follow-up, in contrast to our results. In this PARTNER
Trial substudy, frailty was estimated by the composite of
four items, e.g. gait speed, grip strength, ADL scores and
albumin, and almost 50% of the patients was classified as
frail [11]. In our study, we use a different frailty score (EFS)
where a more comprehensive set of frailty assessment tools
are combined and where 30% of our patients were classified
as frail, possibly indicating a more strict definition of frailty.
Differences in HRQoL outcomes between the PARTNER
Trial substudy and our study could be explained by the
difference in frailty definition. There is still a lack of consen-
sus of defining frailty in an optimal frailty assessment [33].
Frail patients are impaired in physical activity, endurance,
mobility, strength, etc., because of diminished physiological
reserve [34,35]; therefore treating AS alone might not be suf-
ficient to improve overall HRQoL because there still remain
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improvement in NYHA class in 50% of frail patients, this
did not translate into an improvement in general HRQoL.
However, in frail patients, the absence of peripheral artery
disease and renal dysfunction at baseline was associated with
improvement of HRQoL. Renal dysfunction is one of the
most frequent comorbidities in TAVI patients and has been
found to significantly worsen the prognosis of patients at
short- and long-term follow-up [37]. This study shows that
the combination of frailty and certain comorbidities could
be associated with a higher chance of not improving HRQoL
after TAVI. Although frailty has been associated with higher
mortality rates compared to non-frail patients [11–13], sur-
vival rates are still higher compared to conservative ther-
apy [38]. The determination of frailty is one of the many
variables needed in the process of shared decision-making:
concurrent comorbidities, treatment goals, expectations for
the future, possible geriatric interventions and technical
possibilities; all these aspects are unbearable for optimis-
ing treatment for this mostly older, frail and comorbid
patient population. The treatment of this group of patients
calls for intense collaboration between the geriatrician and
cardiologist.
This study has several limitations. First, results should
be interpreted within the framework of a local population,
because of the single-centre aspect of this study. Second, the
Erasmus Frailty Score has not been formally validated in
a different cohort; therefore, it should not be used in the
clinical practice as a risk score to aid decisions. Nonetheless,
we do believe that this frailty score is a reflection of the
patient’s general condition, since it quantifies deficits in geri-
atric domains essential for optimal functioning in patients.
It can be helpful in identifying those patients with frailty
and therefore a higher chance of negative outcomes after
TAVI.
In addition, the study population is relatively small; how-
ever, previously described studies included a similar number
of patients. In this study we used the Eq-5D to measure
general health-related quality of life. Because of its generality,
the Eq-5D might fail to capture and incorporate factors in
valuing QoL, such as socio-economic status, home support
or incorporating events like falls or rehospitalisation.
Further research in a larger cohort focused on postoper-
ative HRQoL and QoL in the broader sense is necessary to
evaluate our current findings.
In conclusion, we found that frailty at baseline was asso-
ciated with deterioration of HRQoL 1 year after TAVI
and with no change of self-estimated health status. How-
ever, HRQoL did improve in frail patients with no periph-
eral arterial disease or renal impairment. Finally, patients
who suffered from postoperative delirium had a poorer out-
come, necessitating more diligence in delirium prevention
strategy.
Supplementary Data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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